A
nkylosing spondylitis (AS) is the most common and the most typical form of spondyloarthropathy. It affects primarily the axial skeleton and it is often associated with peripheral synovitis and the presence of extra-articular manifestations. The use of non-steroidal anti-inflammatory drugs (NSAIDs) at full therapeutic doses and a lifelong programme of regular exercise form the mainstay of management of AS. The use of disease modifying antirheumatic drugs (DMARDs), mainly sulfasalazine (SSZ) and methotrexate (MTX), may be useful in some patients.

Recent studies demonstrated that antitumour necrosis factor α therapy (infliximab) is effective in patients with AS. Indeed, open label and randomised double blind, placebo controlled trials of infliximab given intravenously in a dose of 5 mg/kg of body weight on three occasions (weeks 0, 2, and 6) have demonstrated a quick therapeutic response and a statistically significant improvement in most patients with AS. However, as in rheumatoid arthritis, treatment of AS must be continued because the disease activity returns a few weeks after infliximab is stopped. On the other hand, serious adverse events, including a predisposition to bacterial infections, reactivation of tuberculosis, and demyelinating diseases, are some of the disadvantages of infliximab therapy.

This study was designed to investigate the efficacy and safety of long term infliximab therapy in patients with severe refractory AS.

**Objective:** To evaluate the efficacy and safety of long term infliximab therapy in patients with severe refractory ankylosing spondylitis (AS).

**Patients and methods:** Twenty five patients (24 male, 1 female; mean (SD) age 36.0 (10.5); disease duration 13.8 (8.5) years) with AS fulfilling the modified New York criteria for AS were investigated. Twenty two (88%) patients were HLA-B27 positive. All patients had active axial disease (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >30/100) and C reactive protein (CRP) >10 mg/l, despite adequate treatment. Intravenous infliximab (5 mg/kg) was given at weeks 0, 2, 6, and every eight weeks thereafter for 12 months. The primary end point was the reduction of the patient’s global assessment of pain (GAP) by >20% on a 100 mm visual analogue scale.

**Results:** GAP was reduced by >20% in 23 (92%) patients, by 50% in 21 (84%) patients, and by 70% in 13 (52%). The change in BASDAI and CRP from baseline was statistically significant. The treatment was well tolerated with minimal side effects. One patient dropped out owing to inefficacy and one stopped treatment owing to an allergic reaction.

**Conclusion:** This longer length study confirms the efficacy of infliximab and the good safety profile in patients with AS.

**MATERIALS AND METHODS**

**Study design**

Twenty five patients who fulfilled the modified New York criteria for AS were studied. The patients had had active disease for at least three months and were refractory to many drugs. The current treatment was NSAIDs, mainly indomethacin, in all patients, while three patients were taking SSZ, two MTX, and four patients were also receiving prednisone (5 mg/day). Despite the above treatment all patients had active disease. Therefore, we investigated whether infliximab would provide additional clinical benefit to these patients. The patients were given with intravenous infliximab (5 mg/kg of body weight) at weeks 0, 2, 6, and every eight weeks thereafter, for 12 months. Patients were excluded from the study if they had (a) history or presence of malignant diseases; (b) known liver or kidney abnormalities or history of viral hepatitis B and C; (c) major complicating illnesses such as heart or lung diseases, blood dyscrasias, or amyloidosis; (d) positive tuberculin skin test using PPD/RT23 (2 IU/0.1 ml), or an abnormal chest radiograph suggesting chronic infectious disease, granulomatous disease, or other pathological findings. The protocol was approved by the Institutional Scientific Board of the University Hospital of Ioannina, Greece. Patients were entered into the study after reading and signing an informed consent form.

**Clinical assessment**

Each patient underwent a complete physical examination before treatment at each visit until the end of the study and every two months thereafter. Clinical disease variables included: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Disease Functional Index (BASFI), patient’s global assessment of pain (GAP) on a 100 mm visual analogue scale (100 mm VAS), doctor’s global assessment of disease activity (100 mm VAS), patient’s global assessment of disease activity (100 mm VAS), Schober test (cm), chest expansion (cm), and weight (kg). Laboratory disease variables included C reactive protein (CRP, mg/l), and erythrocyte sedimentation rate (ESR, mm/1st h) that were determined at each patient visit.

The primary end point was the reduction of the GAP by >20%. Secondary end points were the reduction of the pain by 50% and 70%. Although not included in the original

**Abbreviations:** ANA, antinuclear antibodies; AS, ankylosing spondylitis; ASAS, AS Assessment Study Group; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; GAP, global assessment of pain; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; SSZ, sulfasalazine; VAS, visual analogue scale
**Figure 1** Improvement of patient’s global assessment of pain.

![Graph showing improvement of patient's global assessment of pain](image)

The disease was defined as active if patients had BASDAI $\geq 30/100$ and CRP $>10$ mg/l.

**Monitoring**

A complete blood count with differential and platelets count, as well as serum values of liver enzymes, bilirubin, albumin, glucose, creatinine, and urine analysis were obtained before treatment and at each patient visit until the end of the study and every two months thereafter. Additionally, 2 ml blood serum from patients, at each visit, was stored at $-20^\circ$C for measurement of the autoantibody profile.

**Statistics**

Statistical significance was estimated with Wilcoxon’s test for pairs.

**RESULTS**

A total of 30 patients with AS were recruited. Five were excluded: 3 had a positive tuberculin skin test, 1 had congestive heart failure, and 1 had severe restrictive lung disease. Thus, 25 patients (24 male, 1 female) were enrolled. They had a mean age of 36.0 (10.5) years and a disease duration of 13.5 (8.3) years. Twenty two patients were HLA-B27 positive. All patients had axial disease, only one had peripheral synovitis, and 10 patients had a history of anterior uveitis.

A reduction of the GAP of $>20\%$ was achieved in 23 (92%) patients. Additionally, 21 (84%) patients attained a reduction of 50% and 13 (52%) a reduction of 70% (fig 1). This clinical improvement was noticed after the first three infusions and continued throughout the treatment. More specifically, after the third infusion at week 6, the results were significantly different from baseline as shown by reduction in the BASDAI, improvement of the BASFI, and decrease of disease activity according to the patient’s and doctor’s opinions (table 1). Twenty two (84%) patients reached the BASDAI 20% between weeks 6 and 52, and an improvement of BASDAI 50% was reached in 15 (60%) patients between weeks 6 and 52. Additionally, 22 (88%) patients were responders according to the ASAS 20% criteria and 18 (72%) achieved partial remission. Finally, an improvement of the Schober test and of body weight were noted. This clinical improvement was associated with a reduction of CRP and ESR (table 1). The clinical, functional, and laboratory improvement continued throughout the treatment and at week 52 a further statistically significant difference was noticed in the BASDAI, the BASFI, the disease activity according to the patient’s and doctor’s opinions, and the body weight (table 1).

The treatment was well tolerated with mild adverse events. Nine patients experienced adverse events, mainly infections

### Table 2 Adverse events recorded in patients with AS during treatment with infliximab

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Number of patients</th>
<th>Number of events</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common cold</td>
<td>2</td>
<td>4</td>
<td>Resolution</td>
</tr>
<tr>
<td>Sore throat</td>
<td>3</td>
<td>4</td>
<td>Resolution</td>
</tr>
<tr>
<td>Allergic reactions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>2</td>
<td>2</td>
<td>Resolution</td>
</tr>
<tr>
<td>Severe</td>
<td>1</td>
<td>1</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraesthesias</td>
<td>1</td>
<td>1</td>
<td>Resolution</td>
</tr>
<tr>
<td>Total</td>
<td>9</td>
<td>12</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1** Comparison of outcome measures before treatment, after six weeks and after 52 weeks of treatment with infliximab in patients with severe AS

<table>
<thead>
<tr>
<th>Variables</th>
<th>Week 0</th>
<th>Week 6</th>
<th>Week 52</th>
</tr>
</thead>
<tbody>
<tr>
<td>BASDAI</td>
<td>57.7 (19.7)</td>
<td>32.5 (19.5)**</td>
<td>15.4 (16.1)**</td>
</tr>
<tr>
<td>BASFI</td>
<td>38.3 (22.2)</td>
<td>33.3 (16.2)**</td>
<td>16.3 (14.0)**</td>
</tr>
<tr>
<td>Patient’s GAP (100 mm VAS)</td>
<td>65.3 (16.7)</td>
<td>20.1 (18.6)**</td>
<td>20.4 (13.4)***</td>
</tr>
<tr>
<td>Patient’s global assessment of activity (100 mm VAS)</td>
<td>54.1 (18.9)</td>
<td>29.2 (16.4)**</td>
<td>20.8 (12.3)*</td>
</tr>
<tr>
<td>Doctor’s global assessment of disease activity (100 mm VAS)</td>
<td>49.3 (15.5)</td>
<td>26.3 (10.5)**</td>
<td>20.5 (10.0)*</td>
</tr>
<tr>
<td>Schober test (cm)</td>
<td>1.8 (1.6)</td>
<td>2.2 (1.6)*</td>
<td>2.1 (1.4)</td>
</tr>
<tr>
<td>Chest expansion (cm)</td>
<td>1.8 (0.8)</td>
<td>2.3 (1.3)</td>
<td>2.3 (1.3)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74.4 (10.2)</td>
<td>75.5 (9.8)**</td>
<td>78.3 (9.6)**</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>27.1 (21.0)</td>
<td>1.9 (3.4)**</td>
<td>7.5 (13.5)</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>33.9 (19.1)</td>
<td>8.0 (5.9)**</td>
<td>15.8 (21.6)</td>
</tr>
</tbody>
</table>

The numbers in parentheses indicate the standard deviation.

BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Disease Functional Index; GAP, global assessment of pain; VAS, visual analogue scale; CRP, C reactive protein; ESR, erythrocyte sedimentation rate.

* $p<0.05$; ** $p<0.01$; *** $p<0.001$. 

www.annrheumdis.com
DISCUSSION

AS is a chronic inflammatory rheumatic disease which affects primarily the axial skeleton, leading to functional disability and premature death.13 14 Although there is no cure or treatment which shows proven efficacy in preventing disease progression, NSAIDs and physiotherapy have been the basis of AS treatment.2 3 Thus, there is a clear need for effective new treatments for this disease. Extensive rationale exists for the use of tumour necrosis factor α inhibition in AS, and a growing body of evidence demonstrates the clinical efficacy of this approach. Recent, short and long term, open label and randomised, double blind, placebo controlled trials showed that infliximab therapy in patients with active AS was well tolerated and improved global, peripheral, and axial disease activity quickly and significantly.3–15 However, the occurrence of serious adverse events4–6 in some patients necessitated the requirement for strict inclusion criteria and long term treatment and follow up. Thus, our study was designed to investigate the efficacy, tolerability, and safety of infliximab therapy in patients with active AS for a period of 12 months.

Ninety two per cent of patients in this study had a clinical response according to reduction of the GAP by >20%, 84% attained a reduction of 50%, and 52% of patients achieved a reduction of 70%. The degree of improvement is particularly noteworthy in view of the inclusion of patients resistant to any previous treatment and with severe active disease. This clinical improvement was also associated with a reduction of the BASDAI, improvement of the BASFI and Schober test, and increased body weight. In addition, a reduction of CRP and ESR occurred in most patients.

Infusions of infliximab were generally well tolerated. Nine patients developed mild adverse events, mainly infections and allergic reactions and one paraesthesia. All these adverse events were resolved without sequelae. One patient had to stop infliximab therapy owing to an immediate hypersensitivity reaction after the third infusion (table 2). One other patient with longstanding axial disease discontinued the study because of drug inefficacy after the fifth infusion. Finally, 6/25 patients developed positive antinuclear antibodies (ANA) with a titre ranging from 1/160 to 1/640 and all having a fine speckled pattern. No other antibodies were detected.

REFERENCES